United States Biotechnology & Medical Research

Prelude Therapeutics Inc (PRLD)

Track

Track

Prelude Therapeutics Inc. recorded significant insider activity on April 21, 2026, involving substantial share acquisitions by David P. Bonita and OrbiMed Advisors LLC. These transactions represent the most recent documented trading. Prior to this, various executives, including the CEO, engaged in multiple purchase events throughout early 2025.
Ticker: PRLD Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Prelude Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
3.1
Bonita David P Non-Executive Director Large shareholder
Transaction date
Purchase
Price
357.19
Quantity 61,812 -48.2%
Value US$3,508,654
3.1
Bonita David P Non-Executive Director Large shareholder
Transaction date
Purchase
Price
166.86
Quantity 58,143 +42.1%
Value US$4,129,814
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
401.12
Quantity 97,280 -6.0%
Value US$861,094
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
4.44
Quantity 1,689,189 +16.7%
Value US$7,499,999
1.2
Combs Andrew Chief Chemistry Officer Officer
Transaction date
Planned purchase
Price
0.69
Quantity 100,000 +26.3%
Value US$69,250
3.8
Vaddi Krishna CEO Executive Director
Transaction date
Purchase
Price
0.69
Quantity 675,000 +51.0%
Value US$467,438
3.8
Vaddi Krishna CEO Executive Director
Transaction date
Purchase
Price
0.73
Quantity 15,000 +1.1%
Value US$10,959
3.8
Vaddi Krishna CEO Executive Director
Transaction date
Purchase
Price
0.73
Quantity 5,416 +0.4%
Value US$3,950
3.8
Vaddi Krishna CEO Executive Director
Transaction date
Purchase
Price
0.75
Quantity 9,106 +0.7%
Value US$6,829
3.8
Vaddi Krishna CEO Executive Director
Transaction date
Purchase
Price
0.75
Quantity 29,999 +2.4%
Value US$22,631
3.8
Vaddi Krishna CEO Executive Director
Transaction date
Purchase
Price
0.72
Quantity 50,000 +4.1%
Value US$35,820
3.8
Vaddi Krishna CEO Executive Director
Transaction date
Purchase
Price
0.71
Quantity 47,500 +4.1%
Value US$33,744
3.8
Vaddi Krishna CEO Executive Director
Transaction date
Purchase
Price
1.21
Quantity 5,000 +3.6%
Value US$6,044
3.8
Vaddi Krishna CEO Executive Director
Transaction date
Purchase
Price
1.20
Quantity 10,000 +7.8%
Value US$12,000
1.2
Combs Andrew Chief Chemistry Officer Officer
Transaction date
Purchase
Price
1.37
Quantity 60,000 +18.9%
Value US$82,002
1.2
Combs Andrew Chief Chemistry Officer Officer
Transaction date
Planned purchase
Price
1.15
Quantity 3,075 +1.0%
Value US$3,536
1.9
Lim Bryant David CLO, Interim CFO, Corp Sec. Officer
Transaction date
Purchase
Price
0.91
Quantity 25,000 +1041.7%
Value US$22,638
3.8
Vaddi Krishna CEO Executive Director
Transaction date
Purchase
Price
0.89
Quantity 6,888 +5.7%
Value US$6,116
3.8
Vaddi Krishna CEO Executive Director
Transaction date
Purchase
Price
0.93
Quantity 100,000 +9.4%
Value US$93,210
3.8
Vaddi Krishna CEO Executive Director
Transaction date
Purchase
Price
5.31
Quantity 900 +0.1%
Value US$4,779
3.8
Vaddi Krishna CEO Executive Director
Transaction date
Purchase
Price
5.01
Quantity 1,000 +0.1%
Value US$5,011
1.9
Lim Bryant David Chief Legal Officer, Corp Sec. Officer
Transaction date
Purchase
Price
5.39
Quantity 2,400 +inf%
Value US$12,936
3.8
Vaddi Krishna CEO Executive Director
Transaction date
Purchase
Price
5.63
Quantity 11,856 +1.1%
Value US$66,749
3.6
Chardonnet Laurent Chief Financial Officer Officer
Transaction date
Planned purchase
Price
5.50
Quantity 5,000 +13.5%
Value US$27,500
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
5.75
Quantity 869,565 +9.4%
Value US$4,999,999
3.1
Bonita David P Non-Executive Director Large shareholder
Transaction date
Purchase
Price
5.75
Quantity 869,565 +9.4%
Value US$4,999,999
2.5
Huang Jane President, CMO Officer
Transaction date
Sale
Price
6.12
Quantity 13,280 -35.4%
Value US$81,274
3.8
Vaddi Krishna CEO Executive Director
Transaction date
Purchase
Price
5.13
Quantity 19,188 +18.9%
Value US$98,446
3.6
Chardonnet Laurent Chief Financial Officer Officer
Transaction date
Planned purchase
Price
4.76
Quantity 10,000 +38.7%
Value US$47,600
3.6
Chardonnet Laurent Chief Financial Officer Officer
Transaction date
Purchase
Price
4.23
Quantity 10,000 +69.0%
Value US$42,300
Morosini Deborah EVP, Chief of Clinical Affairs Officer
Transaction date
Planned sale
Price
13.00
Quantity 28,751 -98.5%
Value US$373,763
1.2
Combs Andrew EVP, Head of Chemistry Officer
Transaction date
Purchase
Price
11.60
Quantity 4,000 +1.5%
Value US$46,400
1.2
Combs Andrew EVP, Head of Chemistry Officer
Transaction date
Purchase
Price
12.12
Quantity 4,000 +1.5%
Value US$48,480
Morosini Deborah EVP, Chief of Clinical Affairs Officer
Transaction date
Planned sale
Price
16.43
Quantity 400 -47.4%
Value US$6,570
Morosini Deborah EVP, Chief of Clinical Affairs Officer
Transaction date
Planned sale
Price
15.87
Quantity 28,351 -97.1%
Value US$449,962
Mauro David J Chief Medical Officer Officer
Transaction date
Planned sale
Price
32.06
Quantity 1,289 -100.0%
Value US$41,330
Mauro David J Chief Medical Officer Officer
Transaction date
Planned sale
Price
31.30
Quantity 7,803 -85.8%
Value US$244,257
Mauro David J Chief Medical Officer Officer
Transaction date
Planned sale
Price
30.26
Quantity 5,908 -39.4%
Value US$178,762
Mauro David J Chief Medical Officer Officer
Transaction date
Planned sale
Price
32.73
Quantity 12,700 -100.0%
Value US$415,665
Mauro David J Chief Medical Officer Officer
Transaction date
Planned sale
Price
31.62
Quantity 900 -6.6%
Value US$28,462
Mauro David J Chief Medical Officer Officer
Transaction date
Planned sale
Price
30.35
Quantity 1,400 -9.3%
Value US$42,496
Piper Brian Chief Financial Officer Officer
Transaction date
Planned sale
Price
36.09
Quantity 399 -100.0%
Value US$14,401
Piper Brian Chief Financial Officer Officer
Transaction date
Planned sale
Price
35.45
Quantity 1,736 -81.3%
Value US$61,536
Piper Brian Chief Financial Officer Officer
Transaction date
Planned sale
Price
34.11
Quantity 3,088 -59.1%
Value US$105,338
Piper Brian Chief Financial Officer Officer
Transaction date
Planned sale
Price
33.53
Quantity 3,110 -37.3%
Value US$104,263
Scherle Peggy Chief Scientific Officer Officer
Transaction date
Planned sale
Price
41.85
Quantity 200 -0.1%
Value US$8,370
Scherle Peggy Chief Scientific Officer Officer
Transaction date
Planned sale
Price
41.14
Quantity 5,836 -3.3%
Value US$240,090
Scherle Peggy Chief Scientific Officer Officer
Transaction date
Planned sale
Price
40.30
Quantity 3,964 -2.2%
Value US$159,732
Mauro David J Chief Medical Officer Officer
Transaction date
Planned sale
Price
41.07
Quantity 1,109 -100.0%
Value US$45,545
Mauro David J Chief Medical Officer Officer
Transaction date
Planned sale
Price
40.30
Quantity 10,476 -90.4%
Value US$422,148
Mauro David J Chief Medical Officer Officer
Transaction date
Planned sale
Price
39.36
Quantity 3,415 -22.8%
Value US$134,399
Pierce Christopher EVP and Chief of Business Oper Officer
Transaction date
Planned sale
Price
40.29
Quantity 3,295 -46.8%
Value US$132,765
Morosini Deborah EVP, Chief of Clinical Affairs Officer
Transaction date
Planned sale
Price
40.29
Quantity 3,223 -87.9%
Value US$129,853
Mauro David J Chief Medical Officer Officer
Transaction date
Planned sale
Price
36.11
Quantity 1,711 -100.0%
Value US$61,791
Mauro David J Chief Medical Officer Officer
Transaction date
Planned sale
Price
35.68
Quantity 15,601 -90.1%
Value US$556,580
Mauro David J Chief Medical Officer Officer
Transaction date
Planned sale
Price
34.66
Quantity 7,688 -30.8%
Value US$266,478
Mauro David J Chief Medical Officer Officer
Transaction date
Planned sale
Price
31.27
Quantity 4,000 -100.0%
Value US$125,077
Mauro David J Chief Medical Officer Officer
Transaction date
Planned sale
Price
30.82
Quantity 21,000 -84.0%
Value US$647,272
Pierce Christopher EVP and Chief of Business Oper Officer
Transaction date
Planned sale
Price
40.00
Quantity 200 -5.1%
Value US$8,000
Scherle Peggy Chief Scientific Officer Officer
Transaction date
Planned sale
Price
39.57
Quantity 1,669 -1.0%
Value US$66,040
Scherle Peggy Chief Scientific Officer Officer
Transaction date
Planned sale
Price
38.97
Quantity 669 -0.4%
Value US$26,073
Scherle Peggy Chief Scientific Officer Officer
Transaction date
Planned sale
Price
37.72
Quantity 875 -0.5%
Value US$33,003
Scherle Peggy Chief Scientific Officer Officer
Transaction date
Planned sale
Price
36.97
Quantity 1,417 -0.8%
Value US$52,387
Scherle Peggy Chief Scientific Officer Officer
Transaction date
Planned sale
Price
40.30
Quantity 200 -0.1%
Value US$8,060
Scherle Peggy Chief Scientific Officer Officer
Transaction date
Planned sale
Price
39.63
Quantity 6,881 -3.8%
Value US$272,679
Scherle Peggy Chief Scientific Officer Officer
Transaction date
Planned sale
Price
39.02
Quantity 8,289 -4.4%
Value US$323,405
Mauro David J Chief Medical Officer Officer
Transaction date
Planned sale
Price
39.69
Quantity 7,083 -100.0%
Value US$281,116
Mauro David J Chief Medical Officer Officer
Transaction date
Planned sale
Price
39.03
Quantity 8,300 -54.0%
Value US$323,908
1.2
Combs Andrew EVP, Head of Chemistry Officer
Transaction date
Purchase
Price
19.00
Quantity 1,000 +0.4%
Value US$19,000
Morosini Deborah EVP, Chief of Clinical Affairs Officer
Transaction date
Purchase
Price
19.00
Quantity 444 +inf%
Value US$8,436
2.4
Dier Mardi Non-Executive Director
Transaction date
Purchase
Price
19.00
Quantity 10,000 +inf%
Value US$190,000
Pierce Christopher EVP and Chief of Business Oper Officer
Transaction date
Purchase
Price
19.00
Quantity 3,750 +inf%
Value US$71,250
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
19.00
Quantity 710,500 +343.4%
Value US$13,499,500
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
19.00
Quantity 526,300 +inf%
Value US$9,999,700
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-23 2026-04-21 B Purchase
3.1
Bonita David P
Non-Executive Director Large shareholder
61,812 -48.2%
357.19
US$3,508,654 		61,812 -48.2% 357.19 US$3,508,654
2026-04-23 2026-04-21 B Purchase
3.1
Bonita David P
Non-Executive Director Large shareholder
58,143 +42.1%
166.86
US$4,129,814 		58,143 +42.1% 166.86 US$4,129,814
2026-04-23 2026-04-21 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
97,280 -6.0%
401.12
US$861,094 		97,280 -6.0% 401.12 US$861,094
2026-04-23 2026-04-21 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
1,689,189 +16.7%
4.44
US$7,499,999 		1,689,189 +16.7% 4.44 US$7,499,999
2025-03-27 2025-03-25 PP Planned purchase
1.2
Combs Andrew

Chief Chemistry Officer

Officer
100,000 +26.3%
0.69
US$69,250 		100,000 +26.3% 0.69 US$69,250
2025-03-27 2025-03-25 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
675,000 +51.0%
0.69
US$467,438 		675,000 +51.0% 0.69 US$467,438
2025-03-24 2025-03-21 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
15,000 +1.1%
0.73
US$10,959 		15,000 +1.1% 0.73 US$10,959
2025-03-24 2025-03-20 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
5,416 +0.4%
0.73
US$3,950 		5,416 +0.4% 0.73 US$3,950
2025-03-18 2025-03-17 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
9,106 +0.7%
0.75
US$6,829 		9,106 +0.7% 0.75 US$6,829
2025-03-18 2025-03-14 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
29,999 +2.4%
0.75
US$22,631 		29,999 +2.4% 0.75 US$22,631
2025-03-14 2025-03-13 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
50,000 +4.1%
0.72
US$35,820 		50,000 +4.1% 0.72 US$35,820
2025-03-14 2025-03-12 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
47,500 +4.1%
0.71
US$33,744 		47,500 +4.1% 0.71 US$33,744
2025-01-03 2024-12-31 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
5,000 +3.6%
1.21
US$6,044 		5,000 +3.6% 1.21 US$6,044
2025-01-02 2024-12-30 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
10,000 +7.8%
1.20
US$12,000 		10,000 +7.8% 1.20 US$12,000
2024-12-26 2024-12-23 B Purchase
1.2
Combs Andrew

Chief Chemistry Officer

Officer
60,000 +18.9%
1.37
US$82,002 		60,000 +18.9% 1.37 US$82,002
2024-12-26 2024-12-20 PP Planned purchase
1.2
Combs Andrew

Chief Chemistry Officer

Officer
3,075 +1.0%
1.15
US$3,536 		3,075 +1.0% 1.15 US$3,536
2024-12-20 2024-12-19 B Purchase
1.9
Lim Bryant David

CLO, Interim CFO, Corp Sec.

Officer
25,000 +1041.7%
0.91
US$22,638 		25,000 +1041.7% 0.91 US$22,638
2024-12-20 2024-12-19 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
6,888 +5.7%
0.89
US$6,116 		6,888 +5.7% 0.89 US$6,116
2024-12-20 2024-12-18 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
100,000 +9.4%
0.93
US$93,210 		100,000 +9.4% 0.93 US$93,210
2023-05-26 2023-05-25 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
900 +0.1%
5.31
US$4,779 		900 +0.1% 5.31 US$4,779
2023-05-26 2023-05-24 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
1,000 +0.1%
5.01
US$5,011 		1,000 +0.1% 5.01 US$5,011
2023-05-25 2023-05-24 B Purchase
1.9
Lim Bryant David

Chief Legal Officer, Corp Sec.

Officer
2,400 +inf%
5.39
US$12,936 		2,400 +inf% 5.39 US$12,936
2023-05-25 2023-05-23 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
11,856 +1.1%
5.63
US$66,749 		11,856 +1.1% 5.63 US$66,749
2023-05-25 2023-05-23 PP Planned purchase
3.6
Chardonnet Laurent

Chief Financial Officer

Officer
5,000 +13.5%
5.50
US$27,500 		5,000 +13.5% 5.50 US$27,500
2023-05-24 2023-05-22 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
869,565 +9.4%
5.75
US$4,999,999 		869,565 +9.4% 5.75 US$4,999,999
2023-05-24 2023-05-22 B Purchase
3.1
Bonita David P
Non-Executive Director Large shareholder
869,565 +9.4%
5.75
US$4,999,999 		869,565 +9.4% 5.75 US$4,999,999
2023-04-06 2023-04-06 S Sale
2.5
Huang Jane

President, CMO

Officer
13,280 -35.4%
6.12
US$81,274 		13,280 -35.4% 6.12 US$81,274
2022-12-21 2022-12-20 B Purchase
3.8
Vaddi Krishna

CEO

Executive Director
19,188 +18.9%
5.13
US$98,446 		19,188 +18.9% 5.13 US$98,446
2022-12-12 2022-12-08 PP Planned purchase
3.6
Chardonnet Laurent

Chief Financial Officer

Officer
10,000 +38.7%
4.76
US$47,600 		10,000 +38.7% 4.76 US$47,600
2022-06-01 2022-06-01 B Purchase
3.6
Chardonnet Laurent

Chief Financial Officer

Officer
10,000 +69.0%
4.23
US$42,300 		10,000 +69.0% 4.23 US$42,300
2021-12-17 2021-12-15 PlS Planned sale
Morosini Deborah

EVP, Chief of Clinical Affairs

Officer
28,751 -98.5%
13.00
US$373,763 		28,751 -98.5% 13.00 US$373,763
2021-12-15 2021-12-14 B Purchase
1.2
Combs Andrew

EVP, Head of Chemistry

Officer
4,000 +1.5%
11.60
US$46,400 		4,000 +1.5% 11.60 US$46,400
2021-12-15 2021-12-13 B Purchase
1.2
Combs Andrew

EVP, Head of Chemistry

Officer
4,000 +1.5%
12.12
US$48,480 		4,000 +1.5% 12.12 US$48,480
2021-11-18 2021-11-16 PlS Planned sale
Morosini Deborah

EVP, Chief of Clinical Affairs

Officer
400 -47.4%
16.43
US$6,570 		400 -47.4% 16.43 US$6,570
2021-11-18 2021-11-16 PlS Planned sale
Morosini Deborah

EVP, Chief of Clinical Affairs

Officer
28,351 -97.1%
15.87
US$449,962 		28,351 -97.1% 15.87 US$449,962
2021-10-06 2021-10-05 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
1,289 -100.0%
32.06
US$41,330 		1,289 -100.0% 32.06 US$41,330
2021-10-06 2021-10-05 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
7,803 -85.8%
31.30
US$244,257 		7,803 -85.8% 31.30 US$244,257
2021-10-06 2021-10-05 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
5,908 -39.4%
30.26
US$178,762 		5,908 -39.4% 30.26 US$178,762
2021-06-09 2021-06-07 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
12,700 -100.0%
32.73
US$415,665 		12,700 -100.0% 32.73 US$415,665
2021-06-09 2021-06-07 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
900 -6.6%
31.62
US$28,462 		900 -6.6% 31.62 US$28,462
2021-06-09 2021-06-07 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
1,400 -9.3%
30.35
US$42,496 		1,400 -9.3% 30.35 US$42,496
2021-05-27 2021-05-25 PlS Planned sale
Piper Brian

Chief Financial Officer

Officer
399 -100.0%
36.09
US$14,401 		399 -100.0% 36.09 US$14,401
2021-05-27 2021-05-25 PlS Planned sale
Piper Brian

Chief Financial Officer

Officer
1,736 -81.3%
35.45
US$61,536 		1,736 -81.3% 35.45 US$61,536
2021-05-27 2021-05-25 PlS Planned sale
Piper Brian

Chief Financial Officer

Officer
3,088 -59.1%
34.11
US$105,338 		3,088 -59.1% 34.11 US$105,338
2021-05-27 2021-05-25 PlS Planned sale
Piper Brian

Chief Financial Officer

Officer
3,110 -37.3%
33.53
US$104,263 		3,110 -37.3% 33.53 US$104,263
2021-05-11 2021-05-07 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
200 -0.1%
41.85
US$8,370 		200 -0.1% 41.85 US$8,370
2021-05-11 2021-05-07 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
5,836 -3.3%
41.14
US$240,090 		5,836 -3.3% 41.14 US$240,090
2021-05-11 2021-05-07 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
3,964 -2.2%
40.30
US$159,732 		3,964 -2.2% 40.30 US$159,732
2021-05-10 2021-05-05 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
1,109 -100.0%
41.07
US$45,545 		1,109 -100.0% 41.07 US$45,545
2021-05-10 2021-05-05 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
10,476 -90.4%
40.30
US$422,148 		10,476 -90.4% 40.30 US$422,148
2021-05-10 2021-05-05 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
3,415 -22.8%
39.36
US$134,399 		3,415 -22.8% 39.36 US$134,399
2021-04-30 2021-04-29 PlS Planned sale
Pierce Christopher

EVP and Chief of Business Oper

Officer
3,295 -46.8%
40.29
US$132,765 		3,295 -46.8% 40.29 US$132,765
2021-04-30 2021-04-29 PlS Planned sale
Morosini Deborah

EVP, Chief of Clinical Affairs

Officer
3,223 -87.9%
40.29
US$129,853 		3,223 -87.9% 40.29 US$129,853
2021-04-29 2021-04-27 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
1,711 -100.0%
36.11
US$61,791 		1,711 -100.0% 36.11 US$61,791
2021-04-29 2021-04-27 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
15,601 -90.1%
35.68
US$556,580 		15,601 -90.1% 35.68 US$556,580
2021-04-29 2021-04-27 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
7,688 -30.8%
34.66
US$266,478 		7,688 -30.8% 34.66 US$266,478
2021-04-21 2021-04-19 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
4,000 -100.0%
31.27
US$125,077 		4,000 -100.0% 31.27 US$125,077
2021-04-21 2021-04-19 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
21,000 -84.0%
30.82
US$647,272 		21,000 -84.0% 30.82 US$647,272
2021-04-15 2021-04-08 PlS Planned sale
Pierce Christopher

EVP and Chief of Business Oper

Officer
200 -5.1%
40.00
US$8,000 		200 -5.1% 40.00 US$8,000
2021-04-15 2021-04-08 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
1,669 -1.0%
39.57
US$66,040 		1,669 -1.0% 39.57 US$66,040
2021-04-15 2021-04-08 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
669 -0.4%
38.97
US$26,073 		669 -0.4% 38.97 US$26,073
2021-04-15 2021-04-08 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
875 -0.5%
37.72
US$33,003 		875 -0.5% 37.72 US$33,003
2021-04-15 2021-04-08 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
1,417 -0.8%
36.97
US$52,387 		1,417 -0.8% 36.97 US$52,387
2021-04-09 2021-04-07 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
200 -0.1%
40.30
US$8,060 		200 -0.1% 40.30 US$8,060
2021-04-09 2021-04-07 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
6,881 -3.8%
39.63
US$272,679 		6,881 -3.8% 39.63 US$272,679
2021-04-09 2021-04-07 PlS Planned sale
Scherle Peggy

Chief Scientific Officer

Officer
8,289 -4.4%
39.02
US$323,405 		8,289 -4.4% 39.02 US$323,405
2021-04-09 2021-04-07 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
7,083 -100.0%
39.69
US$281,116 		7,083 -100.0% 39.69 US$281,116
2021-04-09 2021-04-07 PlS Planned sale
Mauro David J

Chief Medical Officer

Officer
8,300 -54.0%
39.03
US$323,908 		8,300 -54.0% 39.03 US$323,908
2020-09-29 2020-09-29 B Purchase
1.2
Combs Andrew

EVP, Head of Chemistry

Officer
1,000 +0.4%
19.00
US$19,000 		1,000 +0.4% 19.00 US$19,000
2020-09-29 2020-09-29 B Purchase
Morosini Deborah

EVP, Chief of Clinical Affairs

Officer
444 +inf%
19.00
US$8,436 		444 +inf% 19.00 US$8,436
2020-09-29 2020-09-29 B Purchase
2.4
Dier Mardi
Non-Executive Director
10,000 +inf%
19.00
US$190,000 		10,000 +inf% 19.00 US$190,000
2020-09-29 2020-09-29 B Purchase
Pierce Christopher

EVP and Chief of Business Oper

Officer
3,750 +inf%
19.00
US$71,250 		3,750 +inf% 19.00 US$71,250
2020-09-29 2020-09-25 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
710,500 +343.4%
19.00
US$13,499,500 		710,500 +343.4% 19.00 US$13,499,500
2020-09-29 2020-09-25 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
526,300 +inf%
19.00
US$9,999,700 		526,300 +inf% 19.00 US$9,999,700
Explore more

More insider trading research around Prelude Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America